Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GPR6 | P46095 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.30 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9781917 | 0.81 | ALDH1A1 (0.40) | ALDH1A1NPSR1POLBGAAFAAH | |
| SCHEMBL5529311 | 0.81 | NPSR1 (0.41) | ALDH1A1NPSR1POLBGAAFAAH | |
| SCHEMBL8166868 | 0.81 | NPSR1 (0.37) | ALDH1A1NPSR1POLBGAAFAAH | |
| SCHEMBL417979 | 0.81 | NPSR1 (0.37) | ALDH1A1NPSR1POLBGAAFAAH | |
| SCHEMBL1323848 | 0.79 | — | — | |
| SCHEMBL29654087 | 0.78 | NPSR1 (0.35) | ALDH1A1NPSR1POLBGAAFAAH | |
| Hydrochloric Acid SCHEMBL11592382 | 0.77 | NPSR1 (0.53) | ALDH1A1NPSR1POLBGAAFAAH | |
| SCHEMBL11076055 | 0.76 | FAAH (0.46) | ALDH1A1NPSR1POLBGAAFAAH | |
| SCHEMBL11027876 | 0.76 | KMT2A (0.44) | ALDH1A1NPSR1POLBGAAFAAH | |
| SCHEMBL8718626 | 0.76 | FAAH (0.39) | ALDH1A1NPSR1POLBGAAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103980210-A | Method for preparing D(-)-alpha-(4-ethyl-2,3-dioxopiperazine-1-formamido) p-hydoxyphenylacetic acid | SHANDONG IFT SCIENCE & TECHNOLOGY CO LTD | 2014-08-13 | — | — | CN | claimed |
| US-20240307363-A1 | METHODS FOR TREATING A PULMONARY DISEASE WITH AN ALK-5 (TGF BETA R1) INHIBITOR | THIRONA BIO, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240115664-A1 | Diketopiperazine Salts for Drug Delivery and Related Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2024-04-11 | — | — | US | disclosed |
| EP-4333853-A1 | METHODS FOR TREATING A PULMONARY DISEASE WITH AN ALK-5 (TGF BETA R1) INHIBITOR | Thirona Bio, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117615765-A | Methods of treating pulmonary diseases with ALK-5 (TGF beta R1) inhibitors | 蒂罗纳生物股份有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-11872265-B2 | Diketopiperazine salts for drug delivery and related methods | MANNKIND CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2022235621-A1 | METHODS FOR TREATING A PULMONARY DISEASE WITH AN ALK-5 (TGF BETA R1) INHIBITOR | THIRONA BIO, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20210138041-A1 | Diketopiperazine salts for drug delivery and related methods | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2021-05-13 | — | — | US | disclosed |
| US-10912821-B2 | Diketopiperazine salts for drug delivery and related methods | MANNKIND CORPORATION (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200164044-A1 | DIKETOPIPERAZINE SALTS FOR DRUG DELIVERY AND RELATED METHODS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2020-05-28 | — | — | US | disclosed |
| CN-101027057-A | Diketopiperazine, morpholine or dioxane salts for drug delivery | MANNKIND CORP (US) | 2007-08-29 | — | — | CN | disclosed |
| EP-1791542-A1 | DIKETOPIPERAZINE SALTS, DIKETOMORPHOLINE SALTS OR DIKETODIOXANE SALTS FOR DRUG DELIVERY | Mannkind Corporation (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006023943-A1 | DIKETOPIPERAZINE SALTS, DIKETOMORPHOLINE SALTS OR DIKETODIOXANE SALTS FOR DRUG DELIVERY | MANNKIND CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060040953-A1 | Diketopiperazine salts for drug delivery and related methods | MANNKIND CORPORATION (US) | 2006-02-23 | — | — | US | disclosed |
| EP-0249176-A3 | Process for the preparation of 2,3-dioxo-4-oxycarbonyl piperazine derivatives | BASF Aktiengesellschaft (DE) | 1989-01-25 | — | — | EP | disclosed |
| EP-0249176-A2 | Process for the preparation of 2,3-dioxo-4-oxycarbonyl piperazine derivatives | BASF Aktiengesellschaft (DE) | 1987-12-16 | — | — | EP | disclosed |
| EP-0249176-A2 | Process for the preparation of 2,3-dioxo-4-oxycarbonyl piperazine derivatives | BASF Aktiengesellschaft (DE) | 1987-12-16 | — | — | EP | disclosed |
| US-4051102-A | Bicyclic hindered amino acids, metal salts thereof and stabilized compositions | CIBA-GEIGY CORPORATION (US) | 1977-09-27 | — | — | US | disclosed |
| US-3928330-A | Substituted piperazinedione carboxylic acids and metal salts thereof | CIBA GEIGY CORP | 1975-12-23 | — | — | US | disclosed |
| US-3928330-A | Substituted piperazinedione carboxylic acids and metal salts thereof | CIBA GEIGY CORP | 1975-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307363-A1 | METHODS FOR TREATING A PULMONARY DISEASE WITH AN ALK-5 (TGF BETA R1) INHIBITOR | ALK, TGFBR1, TGFBR2 | ALDH1A1 4059/4885NPSR1 713/4885POLB 2955/4885 |
| US-20200164044-A1 | DIKETOPIPERAZINE SALTS FOR DRUG DELIVERY AND RELATED METHODS | DPP7, DPP4, NPY5R | ALDH1A1 1329/4885NPSR1 184/4885POLB 4104/4885 |
| US-20210138041-A1 | Diketopiperazine salts for drug delivery and related methods | DPP7, DPP4, NPY5R | ALDH1A1 1329/4885NPSR1 184/4885POLB 4104/4885 |
| US-11872265-B2 | Diketopiperazine salts for drug delivery and related methods | DPP7, DPP4, NPY5R | ALDH1A1 1329/4885NPSR1 184/4885POLB 4104/4885 |
| US-10912821-B2 | Diketopiperazine salts for drug delivery and related methods | DPP7, DPP4, NPY5R | ALDH1A1 1329/4885NPSR1 184/4885POLB 4104/4885 |
| US-20240115664-A1 | Diketopiperazine Salts for Drug Delivery and Related Methods | DPP7, DPP4, NPY5R | ALDH1A1 1329/4885NPSR1 184/4885POLB 4104/4885 |
| US-20060040953-A1 | Diketopiperazine salts for drug delivery and related methods | DNPEP, DPP7, NPPA | ALDH1A1 2711/4885NPSR1 155/4885POLB 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.